Research article summary (published 18 Aug 2009):

Solifenacin for therapy resistant overactive bladder.

Full Abstract

PURPOSE: With the availability of the once daily oral antimuscarinic agent solifenacin (5 mg), we started to use it for therapy resistant overactive bladder. We evaluate side effects and efficacy. MATERIAL AND METHODS: We reviewed the charts of children treated with solifenacin succinate between August 2005 and August 2008 for therapy resistant OAB. Incontinence was compared at study entry and study end. RESULTS: During the study period 84 boys and 54 girls with a mean age of 9 years 2 months received solifenacin. Mean followup was 22.59 months. While on solifenacin, side effects were observed in 9 of 138 patients (6.5%). Efficacy evaluation included only 99 patients after 3 months of therapy. Mean voided volume after treatment was 253.5 ml, showing a significant 25% increase compared to the mean value before therapy (50.5 vs 203.0 ml, p <0.01). Of the patients 84 (85%) were considered responders, including 45 who were completely dry (full response) and 39 who had fewer nocturnal enuresis or diurnal incontinence symptoms (partial response). Of these 39 patients 17 became dry during the day, 1 became dry during the night and 21 had more than a 50% decrease in nocturnal enuresis and diurnal incontinence symptoms. In 15 patients the outcome was unchanged or worse (no response). CONCLUSION: In this group of children with OAB we noted favorable results with solifenacin with few side effects. Despite the uncontrolled, retrospective study design the effect is attributable to solifenacin intake.

Author information

Author/s: Hoebeke, Piet (P); De Pooter, Jan (J); De Caestecker, Karel (K); Raes, Ann (A); Dehoorne, Joke (J); Van Laecke, Erik (E); Vande Walle, Johan (J);

Affiliation: Division of Pediatric Urology, Department of Urology, Ghent University Hospital, Ghent, Belgium. Piet.hoebeke(-atsign-)ugent.be

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: The Journal of urology (J Urol), published in United States. (Language: eng)

Reference: 2009-Oct; vol 182 (issue 4 Suppl) : pp 2040-4

Dates: Created 2009/09/14; Completed 2009/10/29;

PMID: 19695608, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adolescent Child Child, Preschool Female Humans Male

Muscarinic Antagonists - therapeutic use Quinuclidines - therapeutic use Retrospective Studies Tetrahydroisoquinolines - therapeutic use Treatment Outcome Urinary Bladder, Overactive - drug therapy

Associated Chemicals: Muscarinic Antagonists (0) ; Quinuclidines (0) ; Tetrahydroisoquinolines (0) ; quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate (0)

Related articles

These are the highest related articles currently in the database:

• [Overactive bladder. When it's pressing, immediate help is indicated] 13 May 2008
• [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV] 29 Nov 2008
• Solifenacin. 30 Oct 2006
• [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder] 29 Nov 2006
• [Urinary urgency] 29 Jul 2008
• Solifenacin succinate for the treatment of symptoms of overactive bladder. 30 Aug 2006
• Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. 30 Aug 2006
• Overactive bladder treatments in early phase clinical trials. 29 Jun 2007
• Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. 29 Nov 2006
• Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. 4 Oct 2008

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.